Strategic Partnerships NAMSA is pursuing and formalizing strategic partnerships with other CROs and service providers (example: Lexitas Pharma Services) and has a history of outsourcing collaborations (Terumo). This indicates potential upsell opportunities for expanded end-to-end development services, regulatory consulting, and clinical research capabilities through partner ecosystems.

Leadership Expansion Recent executive appointments and business development leadership changes (VP of Clinical and Consulting Business Development) signal renewed growth focus and a push into broader markets. Engage for strategic alignment on expanded service offerings, joint go-to-market initiatives, and larger-scale program management engagements.

Acquisition & Asset Growth NAMSA’s acquisitions and facility investments (including WuXi AppTec facilities and international expansions) show a capacity to scale operations and access new geographies. Explore opportunities to position NAMSA for global clinical and regulatory programs, including site-supported testing and regional regulatory strategy.

Clinical & Regulatory Depth Positioned as a first-stop MedTech CRO with end-to-end capabilities spanning clinical research, regulatory, reimbursement, quality consulting, and biocompatibility testing. Market-ready opportunities exist for comprehensive development programs, risk-based testing, and faster time-to-market for medical devices.

Ophthalmic Focus Recent ophthalmic development partnership with Lexitas signals a targeted vertical opportunity. Consider offering specialized ophthalmic study design, regulatory submissions, and device testing services to capitalize on this sector’s growth and NAMSA’s demonstrated domain expertise.